Prediction Case File
YouTubeTracking Live

Friends! In this video, I'm going to do a Nebius stock analysis & discuss the risks and upside potential of NBIS stock

1 extracted signal · 0 resolved · 1 still active

The Patient Investor profile imageThe Patient InvestorIndependent analyst profile
Source published
25 Aug 2025, 22:18 UTC
Recorded by Tahlil Plus
18 May 2026, 20:23 UTC
Video preview for Friends! In this video, I'm going to do a Nebius stock analysis & discuss the risks and upside potential of NBIS stock
Source overview

AI-generated source summary

The analysis reviews Nebius Group N.V. (NBIS), a data center and AI workload provider. The company buys GPUs from Nvidia, creates AI workloads, and leases them to smaller companies. The company is known for power efficiency. The group revenue is $105.1 million, with 106% revenue growth quarter-on-quarter and 625% year-on-year. Cash reserves are at $1.68 billion with nearly no debt. However, the video points out a loss from operations is about the same this period as last, not decreasing. The H100 GPU price is $2.00 per hour, The H200 at $2.30. The company is implementing a 20% buyback program over the next 18 months. A Yahoo Finance analysis notes that a 80% use of an H100GPU brings in $1.76 per hour, that with variable costs of $0.32, and $1.14 depreciation, that results in $0.30 per hour. Over a year a GPU generates around 15,400 dollars in revenue. The point the video makes is at the 2.2 dollars per hour, the company needs 2.5 years to make a profit from the GPU, so they must get a lower price for it, or otherwise it would be a loss. The analysis states, 8.5 billion of revenue can be expected in 2029, with the stock trading at 10 times sales resulting in $85 billion market cap. The presenter sets a stock target of $354 for Nebius.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
1
Extracted from this source
Open
1
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    1 eligible signal linked to this case.

  4. Outcome tracking started

    Tahlil Plus began monitoring the extracted predictions.

  5. Live evaluation in progress

    1 signal remains active.

Analyst snapshot

The Patient Investor

Platform-wide history, separate from this source evaluation.

Reliability
47.9
Tracked signals
355
Historical success
34.9%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail